此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis

2017年4月5日 更新者:Peking Union Medical College Hospital

Safety and Diagnostic Performance of 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis

Inflammation mediated by macrophage infiltration plays a vital role in a diverse range of physiological conditions. In particular, recent evidence suggests this type of macrophage response is important for the disease pathology of pulmonary fibrosis. Because cysteine cathepsins are proteases that are highly expressed in antigen presenting cells such as macrophages, they serve as promising biomarkers. Employing non-invasive imaging agents 68Ga-BMV101 that specifically recognize cysteine proteases in immune cells has the potential to not only aid early detection but also significantly aid efforts to monitor progression and patient response to therapy.

研究概览

地位

未知

详细说明

For interests in clinical translation of 68Ga-BMV101, an open-label dynamic whole-body PET/CT study was designed to investigate safety and diagnostic performance of 68Ga-BMV101 in patients with idiopathic pulmonary fibrosis (IPF). A single dose of nearly 111 MBq 68Ga-BMV101 will be intravenously injected into healthy volunteers and patients with suspected IPF. Visual and semiquantitative method will be used to assess the PET/CT images. Changes of blood pressure, pulse, respiration, temperature, routine blood and urine tests, serum alanine aminotransferase, albumin, and creatinine, and any adverse events will be collected from the volunteers. Adverse events will also be observed in the patients.

研究类型

介入性

注册 (预期的)

20

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100730
        • 招聘中
        • Peking Union Medical College Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Patients with idiopathic pulmonary fibrosis

  • Males and females, ≥18 years old
  • Characteristic clinical signs, symptoms and laboratory tests suggesting the diagnosis of IPF.
  • The diagnosis of IPF is based on The Centres for Disease Control and Prevention (CDC) criteria for diagnosing IPF. They rely on a combination of clinical, radiological, operative and histological findings, in addition to results of other laboratory tests.

Exclusion Criteria:

  • Females planning to bear a child recently or with childbearing potential
  • Renal function: serum creatinine >3.0 mg/dL (270 μM/L)
  • Liver function: any hepatic enzyme level more than 5 times upper limit of normal.
  • Known severe allergy or hypersensitivity to IV radiographic contrast.
  • Patients not able to enter the bore of the PET/CT scanner.
  • Inability to lie still for the entire imaging time because of cough, pain, etc.
  • Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
  • Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:68Ga-BMV101 injection and PET/CT scan
The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
其他名称:
  • BMV101 imaging

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Visual and semiquantitative assessment of lesions
大体时间:1 year
Visual analysis will be performed by consensus reading by at least 3 experienced nuclear medicine physician. The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake values (SUVs) of lungs will be measured.
1 year

次要结果测量

结果测量
措施说明
大体时间
不良事件收集
大体时间:5天
对患者和患者进行注射和扫描后 5 天内的不良事件将被跟踪和评估。
5天
Blood pressure
大体时间:24 hours
Blood pressure of patients will be measured at three time points: right before injection, after scanning, and 24 hours after treatment.
24 hours
Pulse
大体时间:24 hours
Pulse will be measured at three time points for each patients: right before injection, after scanning, and 24 hours after treatment.
24 hours
Respiration frequency
大体时间:24 hours
Respiration frequency will be measured at three time points for each patients: right before injection, after scanning, and 24 hours after treatment.
24 hours
Temperature
大体时间:24 hours
Temperature will be measured at three time points for each patients: right before injection, after scanning, and 24 hours after treatment.
24 hours
Routine blood test
大体时间:24 hours
Routine blood test of patients will be measured at two time points: right before injection and 24 hours after treatment.
24 hours
Routine urine test
大体时间:24 hours
Routine urine test of patients will be measured at two time points: right before injection and 24 hours after treatment.
24 hours
Serum alanine aminotransferase
大体时间:24 hours
Serum alanine aminotransferase of patients will be measured at two time points: right before injection and 24 hours after treatment.
24 hours
Serum albumin
大体时间:24 hours
Serum albumin of patients will be measured at two time points: right before injection and 24 hours after treatment.
24 hours
Serum creatinine
大体时间:24 hours
Serum creatinine of patients will be measured at two time points: right before injection and 24 hours after treatment.
24 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年1月1日

初级完成 (预期的)

2017年12月1日

研究完成 (预期的)

2017年12月1日

研究注册日期

首次提交

2015年6月26日

首先提交符合 QC 标准的

2015年6月26日

首次发布 (估计)

2015年6月30日

研究记录更新

最后更新发布 (实际的)

2017年4月7日

上次提交的符合 QC 标准的更新

2017年4月5日

最后验证

2015年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅